Healthcare >> CEO Interviews >> January 13, 2000

Earl M. Collier – Genzyme Surgical Products (gzsp)

Earl M. 'Duke' Collier, is President of Genzyme Surgical Products. Duke Collier joined Genzyme Corporation in 1997, though his relationship with Genzyme, dates to 1990, when, as a consultant, he helped launch the company's first major product, Ceredase. Mr. Collier currently serves as executive vice president of Genzyme Corporation and as president of Genzyme Surgical Products, a tracking stock division of Genzyme Corporation that develops and markets a comprehensive portfolio of instruments, devices, biomaterials and biotherapeutics primarily for the cardiovascular and general surgery markets. Under Mr. Collier's leadership, Genzyme Surgical Products is pioneering the emerging field of biosurgery, which is being created by the increasing convergence of mechanical and biological approaches to surgery and other interventional procedures. Prior to joining Genzyme, Mr. Collier was a partner at the Washington D.C. law firm of Hogan & Hartson. He has served as president of Vitas Healthcare Corporation, and vice president, corporate development and general counsel of Caremark, Inc. He also served as deputy administrator of the Health Care Financing Administration. Mr. Collier earned an A.B. at Yale University and a J.D. at the University of Virginia Law School. He sits on the boards of CareTools, Inc. and Beth Abraham Hospital. Profile
TWST: Give us a brief overview of Genzyme Surgical Products.

Mr. Collier: The history is pretty straightforward. We developed over a

number of years in our biomaterials laboratory the first